A Phase 2 Multicenter Randomized Clinical Trial of CNTF for MacTel

Macular Telangiectasia Type 2 Clinical Trial

Official title:
A Phase 2 Multicenter Randomized Clinical Trial of Ciliary Neurotrophic Factor (CNTF) for Macular Telangiectasia Type 2 (MacTel)

Status Completed

Clinical Trial Summary

This study is a phase 2, randomized, multi-center, single-masked study to evaluate the efficacy and safety of the NT-501 implants in participants with Mactel.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01949324
Study type	Interventional
Source	Neurotech Pharmaceuticals
Contact
Status	Completed
Phase	Phase 2
Start date	April 2014
Completion date	May 22, 2017

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03316300` - A Study to Determine the Safety and Efficacy of NT-501 in Macular Telangiectasia Type 2 - Protocol A	Phase 3
Completed	`NCT03319849` - A Study to Determine the Safety and Efficacy of NT-501 in Macular Telangiectasia Type 2	Phase 3
Completed	`NCT04729972` - Safety Study to Evaluate Bilateral CNTF Implants in Subjects With MacTel Type 2	Phase 2
Active, not recruiting	`NCT04907084` - Serine and Fenofibrate Study in Patients With MacTel Type 2	Phase 2
Not yet recruiting	`NCT06397131` - A Study to Determine the Safety and Efficacy of NT-501 With MHFM	Phase 3